# Targeted Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation

> **NCT05166967** · PHASE3 · COMPLETED · sponsor: **Chinese PLA General Hospital** · enrollment: 204 (actual)

## Conditions studied

- Haploidentical Hematopoietic Stem Cell Transplantation

## Interventions

- **DRUG:** Individual Antithymocyte globulin
- **DRUG:** Antithymocyte globulin

## Key facts

- **NCT ID:** NCT05166967
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-01
- **Primary completion:** 2024-02-16
- **Final completion:** 2025-07-29
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2026-01-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05166967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05166967, "Targeted Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05166967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*